Exelixis
EXEL
#1669
Rank
HK$79.45 B
Marketcap
HK$278.23
Share price
0.82%
Change (1 day)
68.55%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/S ratio for Exelixis (EXEL)

P/S ratio as of November 2024 (TTM): 4.91

According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.49. At the end of 2024 the company had a P/S ratio of 3.56.

P/S ratio history for Exelixis from 2001 to 2024

PS ratio at the end of each year

Year P/S ratio Change
20243.56-12.73%
20234.0826.93%
20223.21-20.32%
20214.03-36.08%
20206.3113.98%
20195.53-19.92%
20186.91-65.24%
201719.9-11.96%
201622.6-34.72%
201534.6207.89%
201411.2-68.88%
201336.1104.02%
201217.7698.31%
20112.22-54.29%
20104.85-7.48%
20095.2416.52%
20084.50-43.54%
20077.97-9.01%
20068.76-15.35%
200510.3-23.26%
200413.538.21%
20039.75-9.02%
200210.7-52.9%
200122.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
1.86-62.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
2.45-50.13%๐Ÿ‡ซ๐Ÿ‡ท France
4.10-16.60%๐Ÿ‡บ๐Ÿ‡ธ USA
2.34-52.37%๐Ÿ‡บ๐Ÿ‡ธ USA
5.32 8.29%๐Ÿ‡บ๐Ÿ‡ธ USA
4.30-12.39%๐Ÿ‡บ๐Ÿ‡ธ USA
2.80-43.06%๐Ÿ‡บ๐Ÿ‡ธ USA
2.58-47.52%๐Ÿ‡บ๐Ÿ‡ธ USA
5.53 12.56%๐Ÿ‡บ๐Ÿ‡ธ USA